Longitudin

Longitudinal study tracks humoral immunity response against SARS-CoV-2 in convalescent individuals

When researchers conducted a longitudinal assessment of humoral immune responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 32 convalescent individuals up to 8 months post-symptom onset, they observed that immunoglobulin (Ig)M levels and the neutralising capacity of plasma in these individuals decreases rapidly, whereas IgG level and Fc-effector activity were more sustained. Meanwhile, SARS-CoV-2-specific B cell immunity persisted despite overall antibody decline. These findings were published in Cell Reports Medicine. “Our findings aid in the understanding o...

Close Monitoring for Heart Risk Needed if Breast, Prostate Cancer Treatment Includes Hormones

The hormonal therapies used to treat many breast and prostate cancers increase the risk of a myocard...

American Heart Association/American Stroke Association Stroke Council Leadership provides guida...

The American Heart Association/American Stroke Association Stroke Council Leadership has provided gu...


Suggested videos

Search:
Date
Filters:
The evolut
8:05

The evolution of hypertension management: The increasing role of triple therapy in clinical practice

Presenter: Giuseppe Mancia
Cardiology : Hypertension
ESH-ISH 2021
Long term
17:22

Long term benefits of blood pressure treatment on the incidence of atrial fibrillation, heart failure and cardiovascular morbidity and mortality: 20-years follow-up of ASCOT-legacy

Presenter: Peter Sever
Cardiology : Hypertension
ESH-ISH 2021
Novel Phar
8:13

Novel Pharmacotherapeutic Strategies for Regaining Control over Alcohol Intake in Alcohol Use Disorder

Presenter: Benjamin Rolland
Psychiatry
EPA 2021
ESH-ISH 20
11:38

ESH-ISH 2021 Late-Breakers Session

Presenter: Anna F. Dominiczak
Cardiology : Hypertension
ESH-ISH 2021
Meeting th
15:41

Meeting the challenges of schizophrenia care during the COVID-19 pandemic

Presenter: Silvana Galderisi
Psychiatry
EPA 2021
Consequenc
7:54

Consequences of COVID-19 Outbreak on Mental Health

Presenter: Celso Arango
Psychiatry
EPA 2021
Obstetric
6:010

Obstetric Complications: The Forgotten Risk Factor for Schizophrenia

Presenter: Robin Murray
Psychiatry
EPA 2021
Detailed s
16:51

Detailed summary of the Consensus Session of the SG-BCC 2021

Presenter: Walter Weber
Oncology : Breast Cancer
St. Gallen BCC 2021
Do we need
6:17

Do we need beta blockers in hypertension?

Presenter: Sverre Erik Kjeldsen
Cardiology : Hypertension
ESH-ISH 2021
Difficult
7:19

Difficult to Treat Depression

Presenter: Andrea Fiorillo
Psychiatry
EPA 2021
Consequenc
7:36

Consequences of COVID-19 Outbreak on Mental Health

Presenter: Axel Börsch-Supan
Psychiatry
EPA 2021
Impact of
11:02

Impact of hypertension in the morbidity and mortality in diabetes mellitus: A real-world data

Presenter: Josep Redon
Cardiology : Hypertension
ESH-ISH 2021
Improving
12:21

Improving the management of hypertension: acting on key factors

Presenter: Neil Poulter
Cardiology : Hypertension
ESH-ISH 2021
No(t) a cl
11:51

No(t) a class effect - A crowded class

Presenter: Athanasios John Manolis
Cardiology : Hypertension
ESH-ISH 2021
Highlights
7:39

Highlights of the EPA 2021

Presenter: Peter Falkai
Psychiatry
EPA 2021
The ISH 20
6:13

The ISH 2020 global hypertension practice guidelines

Presenter: Alta Schutte
Cardiology : Hypertension
ESH-ISH 2021
Carfilzomi
6:49

Carfilzomib, Dexamethasone, and Daratumumab Versus Carfilzomib and Dexamethasone for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis Results from the Randomized, Open-Label, Phase 3 Study Candor

Presenter: Saad Z. Usmani
Hematology
Inhibition
6:22

Inhibition of Complement C1s with Sutimlimab in Patients with Cold Agglutinin Disease (CAD): Results from the Phase 3 Cardinal Study

Presenter: Alexander Röth
Hematology
The QUAZAR
8:20

The QUAZAR AML-001 Maintenance Trial: Results of a Phase III International, Randomized, Double-Blind, Placebo-Controlled Study of CC-486 (Oral Formulation of Azacitidine) in Patients with Acute Myeloid Leukemia (AML) in First Remission

Presenter: Andrew H. Wei
Hematology
Validation
7:11

Validation of BCL11A As Therapeutic Target in Sickle Cell Disease: Results from the Adult Cohort of a Pilot/Feasibility Gene Therapy Trial Inducing Sustained Expression of Fetal Hemoglobin Using Post-Transcriptional Gene Silencing

Presenter: David A. Williams
Hematology
A Randomiz
4:40

A Randomized Phase 3 Trial of Blinatumomab Vs. Chemotherapy As Post-Reinduction Therapy in High and Intermediate Risk First Relapse of B-ALL in Children and Adolescents/Young Adults Demonstrates Superior Efficacy and Tolerability of Blinatumomab

Presenter: Patrick A. Brown
Hematology
CLARIFY -
7:07

CLARIFY - In stable coronary disease, patients with angina and prior myocardial infarction have a poor prognosis despite adherence to guideline recommanded therapies. Final 5-year results from the CLARIFY study

Presenter: Emmanuel Sorbets
Cardiology
SWEDEHEART
5:26

SWEDEHEART: Secondary prevention medication after coronary artery bypass surgery and long-term mortality: A longitudinal population-based study from the SWEDEHEART registry

Presenter: Erik Bjoerklund
Cardiology
ICD use in
4:31

ICD use in HF - Association between implantable cardioverter-defibrillator use for primary prevention and mortality: a prospective propensity-score matched study

Presenter: Benedikt Schrange
Cardiology
PURE: Impa
10:51

PURE: Impact of modifiable risk factors on cardiovascular disease and mortality

Presenter: Salim Yusuf
Cardiology
RAPIDTnT:
5:37

RAPIDTnT: A randomised trial of a 1-hour troponin T protocol in suspected acute coronary syndromes: the Rapid Assessment of Possible ACS In the emergency Department with high sensitivity Troponin T

Presenter: Derek Chew
Cardiology
ENTRUST-AF
7:45

ENTRUST-AF PCI - Edoxaban-based versus vitamin-K-antagonist-based anti-thrombotic regimen following successful coronary stenting in atrial fibrillation patients.

Presenter: Andreas Goette
Cardiology
POPular Ge
6:51

POPular Genetics - Genotype-guided oral P2Y12-inhibition in patients with St-segment elevation myocardial infarction undergoing primary PCI : a randomized, open-label, multicenter trial

Presenter: Jurrien M. Ten Berg
Cardiology
Combined e
5:03

Combined effect of lower LDL-C and lower SBP on the lifetime risk od cardiovascular disease

Presenter: Brian A. Ference
Cardiology
AFIRE - Ri
4:47

AFIRE - Rivaroxaban monotherapy versus dual therapy in patients with atrial fibrillation and stable coronary artery disease

Presenter: Satoshi Yasuda
Cardiology
GALACTIC -
7:23

GALACTIC - Goal-directed AfterLoad Reduction in Acute Congestive Cardiac Decompensation: a randomized controlled trial

Presenter: Christian Eugen Mueller
Cardiology
Salt subst
5:16

Salt substitution and community-wide reduction in blood pressure and hypertension incidence

Presenter: J. Jaime Miranda
Cardiology